• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Stocks

Analyst Bets Compass' 'Magic Mushroom' Approach Is on the Button

Canaccord Genuity analyst Sumant Kulkarni gives the biotech company an $80 price target.
By DEBRA BORCHARDT
Oct 14, 2020 | 03:16 PM EDT
Stocks quotes in this article: CMPS

Compass Pathways (CMPS)  has grabbed the interest of Canaccord Genuity analyst Sumant Kulkarni, who gave the biotech company an $80 price target. The shares are lately trading at approximately $37, so that's a hefty belief that Compass can deliver.

Compass Pathways is a London-based biotech company whose main focus is developing a synthetic version of the natural mushroom substance psilocybin -- a type of hallucinogenic compound. Often called "magic mushrooms," these fungi have long been used by people for a long-lasting psychedelic trip.

Recreational use of psilocybin, however, is not the focus for Compass.

Instead, the company has targeted its compound for TRD, or treatment resistant depression. These are patients suffering from a major depressive disorder and who have tried at least two traditional anti-depressant drugs. The Canaccord report stated that there are only two approved products on the market for TRD at this time, but that they have shortcomings.

"So, the market for TRD translates to tens of billions of dollars at rational branded prices. We model unadjusted peak US/Europe sales for COMP360 of $3.3 billion/1.0 billion in 2021."

Kulkarni is assuming launches in the U.S. in 2025 and gives the probability of approval at 50%.

It should be noted that not only are psychedelic drugs illegal, the number of people who take magic mushrooms for the trip is tiny. According to the Substance Abuse and Mental Health Services Administration, which conducts the largest annual national survey on drug use, only 0.1% of people across all ages were current psychedelic users annually from 2002 to 2014. Being a "current" user means they reported use within 30 days of completing the survey. In 2014, 0.3% of the 11,643 of the respondents who were age 18 to 25 said they were current users. Only 0.1% of 33,750 respondents age 26 or older were.

Compound-ed Interest in Compass 

COMP360 is Compass' proprietary synthetic version of psilocybin and is currently in a phase 2b trial. The trial is a single oral dose given to a patient who is receiving psychological support -- typically called an assisted trip. It's an unconventional approach to treating depression, but there are early reports that patients are responding well to psilocybin treatments. Compass said it expects to deliver top-line data in late 2021.

A Trip With Risks...

Kulkarni outlines the risks involved with Compass. These include educating investors on the use of psilocybin-assisted therapy. There are also unknowns with regards to this type of treatment, such as whether patients will build up tolerance to the drug and whether some patients won't respond at all. There is some skepticism surrounding this type of treatment, too, even as ketamine clinic treatment centers are quickly growing and facing acceptance.

Then there is the study results risk that all biotech firms face. For example, if a study trial doesn't generate the hoped-for results, the company usually faces a share selloff. This can lead to stock volatility.

Even if COMP360 delivers positive study results, there will still be regulatory hurdles to jump over. Psilocybin and psilocyin are both Schedule 1 drugs and would need to be rescheduled. This brings in licensing issues and Drug Enforcement Administration restrictions.

The analyst does bring up the idea intellectual property challenges, but suggests that it is really only possible generics coming into play. Vince Sliwoski of law firm Harris Bricken wrote, "If COMP360 performs well in current trials, a lot of people stand to benefit. Hopefully COMP360 expands rather than limits the seemingly vast potential of magic mushrooms. If it does not, the fallout will be deeply felt. Even compared to the cannabis community, the magic mushrooms crowd is decidedly anti-corporate and impassioned with respect to ownership claims on the compound. Psilocybin advocates will be watching COMPASS closely."

Other than COMP 360, there is little information about other items in the Compass pipeline. The company has said it is targeting other disorders like anorexia, bipolar depression, and chronic cluster headaches. Plus, this is the first drug that Compass has developed -- it isn't an established bio tech company. It could make a lot of mistakes. While it is well-capitalized now, with a cash runway through 2022, that doesn't guarantee the company won't need to raise more money.

...And Benefits

Of course, many of the risks outlined above are valid, but the promise of being able to treat so many people draws hope among investors. The World Health Organization estimates that over 17 million in the U.S. suffer from depression. The TRD patient group could number between two million to three million. Since the product is synthetic, production and delivery are more controllable than those using natural psilocybin. Plus, the safety profile looks to have registered this drug as having a low rate of abuse and only one reported death that was deemed unlikely to be treatment related.

Early findings are showing that one treatment lasts upwards of six months for patients, and it is well-tolerated with low side effects. The costs are estimated to be between $17,000-$25,000 per patient. But if treatment lasts six months insurance companies may be willing to take that price.

Kulkarni is estimating U.S. sales of $108 million in 2025, the expected launch year and $3.3 billion in 2031. He is giving it a Buy rating.

Debra Borchardt has no position in any company mentioned in this story.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

At the time of publication, Borchardt had no position in the securities mentioned.

TAGS: Investing | Stocks | Biotechnology | Health Care Equipment & Services | Healthcare | Cannabis

More from Stocks

Traders: Keep Your Fingers on the Trigger and Targets on a Bottom

James "Rev Shark" DePorre
Mar 4, 2021 4:39 PM EST

As the correction goes on, here's what to do now.

There's Nothing Pleasant About the Current Action

Timothy Collins
Mar 4, 2021 3:00 PM EST

The next good sized bounce in SPAC names, and maybe ARKK names, might be the last exit off the bagholder highway.

Nike's Charts and Indicators Are Still Bearish

Bruce Kamich
Mar 4, 2021 2:20 PM EST

Avoid the long side.

Listen to Mr. Market, Not Mr. Powell

Jim Collins
Mar 4, 2021 1:56 PM EST

Let's look at bonds, rates and, especially, inflation for a true picture of what's going on, and where to put your money.

Powell Supplies the Bears With Ammunition

James "Rev Shark" DePorre
Mar 4, 2021 1:20 PM EST

Picking good stocks is not going to help you much in this market right now.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 10:53 AM EST GARY BERMAN

    Nasdaq Composite: Some Backing and Filling Is Here

    As today is the 4th day of the month, it seems lik...
  • 07:59 AM EST PAUL PRICE

    Fabulous News on United Natural Foods (UNFI)

    The major potential risk factor for , its contrac...
  • 08:50 AM EST PAUL PRICE

    Michaels: Close to a Deal?

    It appears that a deal could be announced soon. ...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login